drugset
Drugs / Autologous Non-Hematopoietic Peripheral Blood Stem Cells
last change Nov 2021 re-read 3 minutes ago

Autologous Non-Hematopoietic Peripheral Blood Stem Cells

also known as NHPBSC · PB-NHESC-C

Cell therapy

Developed for
COVID-19
Investigated by
Abu Dhabi Stem Cells Center

Trials 1

today NCT04473170 · Ph 1/2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04473170 Apr → May 2020 COVID-19 Abu Dhabi Stem Cells Center Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Autologous Non-Hematopoietic Peripheral Blood Stem Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04473170 ↗
Known as NHPBSC “SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care.” NCT04473170 ↗
Known as PB-NHESC-C “using an autologous peripheral blood non-hematopoietic enriched stem cell cocktail (PB-NHESC-C) administered by compressor (jet) nebulization as a complement to standard care therapy.” PMID 34746417 ↗ Nov 2021
Modality Cell therapy “Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy” NCT04473170 ↗
Route Inhaled “through jet nebulization” NCT04473170 ↗